InvestorsHub Logo
Followers 3156
Posts 961111
Boards Moderated 205
Alias Born 09/04/2000

Re: None

Tuesday, 08/30/2022 11:54:37 AM

Tuesday, August 30, 2022 11:54:37 AM

Post# of 6723
abus About AB-729

AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using Arbutus’ novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABUS News